Topical therapies for glaucoma: What family physicians need to know

Keyphrases

• Allergic Reaction 33%
• Alpha Agonist 33%
• Apraclonidine 33%
• Beta-blockers 33%
• Brimonidine 33%
• Brinzolamide 33%
• Carbonic Anhydrase Inhibitors 33%
• Conjunctival 33%
• Dorzolamide 33%
• Family Physicians 100%
• Glaucoma 100%
• Glaucoma Medication 33%
• Glaucoma Treatment 33%
• Iris pigmentation 33%
• Latanoprost 66%
• Low Intraocular Pressure 33%
• Medication Classes 33%
• Miotics 33%
• Need to Know 100%
• New Agents 33%
• Oral Medication 33%
• Prostaglandin Analogs 33%
• Severe Reactions 33%
• Sympathomimetic 33%
• Systemic Side Effects 33%
• Topical Administration 33%
• Topical Agents 66%
• Topical Carbonic Anhydrase Inhibitors 33%
• Topical Therapy 100%
• Visual Field 33%

Medicine and Dentistry

• Alpha-Adrenergic Agonist 25%
• Apraclonidine 25%
• Beta Adrenergic Receptor Blocking Agent 25%
• Brimonidine 25%
• Brinzolamide 25%
• Carbonate Dehydratase Inhibitor 50%
• Dorzolamide 25%
• Drug Therapy 75%
• Glaucoma 100%
• Glaucoma Medication 25%
• Intraocular Pressure 25%
• Iris 25%
• Latanoprost 50%
• Miotic Agent 25%
• Pigmentation 25%
• Prostaglandin Derivative 25%
• Side Effect 50%
• Skin Allergy 25%
• Sympathomimetic Drug 25%
• Topical Agent 50%
• Topical Drug Administration 25%
• Topical Treatment 100%
• Visual Field 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Adrenergic Receptor Stimulating Agent 25%
• Alpha Adrenergic Receptor Stimulating Agent 25%
• Apraclonidine 25%
• Beta Adrenergic Receptor Blocking Agent 25%
• Brimonidine 25%
• Brinzolamide 25%
• Carbonate Dehydratase Inhibitor 50%
• Dorzolamide 25%
• Glaucoma 100%
• Glaucoma Medication 25%
• Latanoprost 50%
• Miotic Agent 25%
• Prostaglandin Analogue 25%
• Side Effect 50%
• Skin Allergy 25%
• Topical Agent 50%